Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act as it was reintroduced yesterday in the new Congress. “The CREATES Act will help ensure that brand-name pharmaceutical companies cannot take advantage of regulatory rules to forestall the competition that is essential for access and innovation,” the groups said in a letter to the bill’s sponsors, Sens. Chuck Grassley, R-Iowa, Patrick Leahy, D-Vt., Amy Klobuchar, D-Minn., and Mike Lee, R-Utah. “With its enactment, the CREATES Act will save patients and taxpayers $3.9 billion over 10 years, according to the Congressional Budget Office, by allowing lower-priced generic drugs to enter the market earlier. We also recognize and appreciate the commitment from Health and Human Services Secretary Alex Azar and Food and Drug Administration Commissioner Scott Gottlieb, M.D., on this important issue. Both have elevated awareness of brand manufacturer ‘gaming’ of FDA regulatory rules to deny would-be generic competitors the ability to purchase samples of brand-name drugs necessary to conduct the FDA-required testing and bring more affordable medicines to market.”

Headline
The AHA April 29 urged House and Senate appropriations committee leaders to fund health care programs that have been successful in improving access to care for…
Headline
The Food and Drug Administration April 28 announced its plan to advance the implementation of real-time clinical trials, which invite participants to supply…
Headline
The AHA submitted a statement for the record to the House Ways and Means Committee for its April 28 hearing with health system CEOs.In the statement, the AHA…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Blog
Public
The American Hospital Association Leadership Summit will take place July 12-14 at the Colorado Convention Center in Denver. Renowned speakers from across…
Headline
The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is…